{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:10:17Z","timestamp":1789027817975,"version":"build-2803163510"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To investigate the prognostic impact of risk organ involvement and baseline metabolic activity assessed by staging\n                      <jats:sup>18<\/jats:sup>\n                      F-fluorodeoxyglucose (FDG) PET\/computed tomography (CT) in newly diagnosed pediatric Langerhans cell histiocytosis (LCH).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Thirty-two children with histologically confirmed LCH who underwent baseline\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT were retrospectively analyzed. Age, disease extent (single-system vs. multisystem), risk organ involvement (RO\u2212 vs. RO+), and baseline metabolic parameters [maximum standardized uptake value (SUV\n                      <jats:sub>max<\/jats:sub>\n                      ), SUV\n                      <jats:sub>mean<\/jats:sub>\n                      , metabolic tumor volume, total lesion glycolysis (TLG), and tumor-to-background ratio (TBR)] were evaluated for their association with progression or relapse. Optimal cut-offs were derived from receiver operating characteristic analysis (Youden index). Survival outcomes were analyzed using Kaplan\u2013Meier and Cox regression models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over a median follow-up of 33 months, disease progression or relapse occurred in 13 patients (40.6%) and was significantly associated with younger age (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.040), higher SUV\n                      <jats:sub>max<\/jats:sub>\n                      (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.016), higher TBR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.007), and TLG (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.033), multisystem LCH (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.004), and risk organ positivity (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001). Risk-organ involvement was the strongest univariate predictor of adverse outcome (hazard ratio: 14.9, 95% confidence interval: 3.3\u201367;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u20050.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Baseline\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT provides important prognostic information in pediatric LCH, with risk organ involvement emerging as the strongest univariate prognostic factor in this cohort, supporting its role in early risk stratification, suggesting a potential role in future risk-adapted treatment planning. Higher SUV\n                      <jats:sub>max<\/jats:sub>\n                      , TBR, and TLG were associated with progression\/relapse in group comparisons, whereas only SUV\n                      <jats:sub>max<\/jats:sub>\n                      and TBR were significantly associated with progression-free survival in univariate Cox analysis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mnm.0000000000002242","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:00:35Z","timestamp":1789027235000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic impact of risk organ involvement and metabolic parameters assessed by staging 18F-FDG PET\/CT in pediatric Langerhans cell histiocytosis"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4183-5824","authenticated-orcid":false,"given":"\u0130pek","family":"\u00d6zt\u00fcrk","sequence":"first","affiliation":[{"name":"Departments of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selin G\u00fcl","family":"Yaran","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fc","family":"Han\u00e7erli","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital, \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enes Mustafa","family":"Kaya","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ay\u00e7i\u00e7ek","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, Ba\u015fak\u015fehir \u00c7am and Sakura City Hospital, \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryem","family":"Kaya","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu Esen","family":"Akka\u015f","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"R1-20260910","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"key":"R2-20260910","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2017.05.059","article-title":"Langerhans cell histiocytosis in children: history, classification, pathobiology, clinical manifestations, and prognosis.","volume":"78","author":"Krooks","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R3-20260910","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjh.18459","article-title":"Incidence, prevalence and survival in patients with Langerhans cell histiocytosis: a National Registry Study from England, 2013-2019.","volume":"199","author":"Liu","year":"2022","journal-title":"Br J Haematol"},{"key":"R4-20260910","first-page":"598","article-title":"Role of 18F-FDG PET\/CT in patients affected by Langerhans cell histiocytosis.","volume":"44","author":"Albano","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-20260910","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12149-023-01892-3","article-title":"The value of 18F-FDG PET\/CT in Langerhans cell histiocytosis.","volume":"38","author":"An","year":"2024","journal-title":"Ann Nucl Med"},{"key":"R6-20260910","first-page":"169","article-title":"Clinical utility of 18F-FDG PET\/CT in adult Langerhans cell histiocytosis: an analysis of 57 patients.","volume":"61","author":"Wu","year":"2020","journal-title":"J Nucl Med"},{"key":"R7-20260910","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.21037\/qims-23-290","article-title":"The baseline metabolism parameters of 18F\u2011FDG PET\/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis.","volume":"13","author":"Lu","year":"2023","journal-title":"Quant Imaging Med Surg"},{"key":"R8-20260910","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4103\/ijnm.ijnm_46_24","article-title":"[18F]FDG-PET\/CT in diagnosis, staging, and management of patients with Langerhans cell histiocytosis.","volume":"39","author":"Priyadharshini","year":"2024","journal-title":"Indian J Nucl Med"},{"key":"R9-20260910","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/pbc.21782","article-title":"Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis.","volume":"52","author":"Phillips","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R10-20260910","doi-asserted-by":"crossref","first-page":"e30057","DOI":"10.1002\/pbc.30057","article-title":"The added value of skeletal surveys in the initial evaluation of children diagnosed with Langerhans cell histiocytosis in the era of staging 18F\u2010FDG PET\/CT: a retrospective study.","volume":"70","author":"Rameh","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"R11-20260910","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/pbc.24367","article-title":"Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years.","volume":"60","author":"Haupt","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R12-20260910","first-page":"37","article-title":"Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children.","volume":"59","author":"Tang","year":"2021","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"R13-20260910","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.26829","article-title":"Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: results from the BCH-LCH 2014 protocol study.","volume":"98","author":"Cui","year":"2023","journal-title":"Am J Hematol"},{"key":"R14-20260910","doi-asserted-by":"crossref","first-page":"100454","DOI":"10.1016\/j.jbo.2022.100454","article-title":"Langerhans cell histiocytosis: a population-based study of anatomical distribution and treatment patterns.","volume":"36","author":"Hu","year":"2022","journal-title":"J Bone Oncol"},{"key":"R15-20260910","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.humpath.2007.03.015","article-title":"Lymph node involvement by Langerhans cell histiocytosis: a clinicopathologic and immunohistochemical study of 20 cases.","volume":"38","author":"Edelweiss","year":"2007","journal-title":"Hum Pathol"},{"key":"R16-20260910","doi-asserted-by":"crossref","first-page":"8385332","DOI":"10.1155\/2022\/8385332","article-title":"Application of 18F-FDG PET\/CT in Langerhans cell histiocytosis.","volume":"2022","author":"Liao","year":"2022","journal-title":"Contrast Media Mol Imaging"},{"key":"R17-20260910","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.21037\/qims-21-823","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of patients with Langerhans cell histiocytosis.","volume":"12","author":"Luo","year":"2022","journal-title":"Quant Imaging Med Surg"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:00:37Z","timestamp":1789027237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MNM.0000000000002242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":17,"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000002242","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"2026-06-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}